Trials / Completed
CompletedNCT03672123
GDF-15 Levels in Risk Stratification in Acute Pulmonary Embolism
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 270 (actual)
- Sponsor
- Medical University of Warsaw · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Prospective observational study evaluating serum GDF-15 levels in patients with acute pulmonary embolism.
Detailed description
Prospective observational study evaluating serum GDF-15 levels in patients with acute pulmonary embolism (APE). In APE right ventricle failure developing due to ischemia and myocarditis is considered the primary cause of death, however, its pathomechanism has not been fully established yet. Growth differentiation factor 15 (GDF-15) is a chemokine secreted by activated macrophages in response to oxidative stress. It has now been shown that ischemic injury, mechanical stretch, and pro-inflammatory cytokines also stimulate the expression of GDF-15 in cardiac myocytes. The objective of this project is to describe the role of GDF-15 in the pathomechanism of acute right ventricle failure in the setting of acute pulmonary embolism and to verify the hypothesis that higher serum concentrations of GDF-15 are associated with more advanced right ventricle dysfunction and failure.
Conditions
Timeline
- Start date
- 2018-09-17
- Primary completion
- 2023-06-30
- Completion
- 2023-06-30
- First posted
- 2018-09-14
- Last updated
- 2023-10-31
Locations
1 site across 1 country: Poland
Source: ClinicalTrials.gov record NCT03672123. Inclusion in this directory is not an endorsement.